Mind / Body Blog

Alzheimer’s Drug Linked to Potentially Serious Muscle Condition

 

Megan Brooks

September 19, 2019

The Alzheimer’s drug donepezil (multiple brands) is associated with a twofold higher risk for hospital admission for rhabdomyolysis, a rare but potentially life-threatening condition in which muscle cells break down. It can lead to kidney damage.

Results of a population-based study showed that use of donepezil was associated a significantly higher risk for rhabdomyolysis compared to other cholinesterase inhibitors, although the investigators note that the absolute risk was small.

“Clinicians should have an index of suspicion to check for rhabdomyolysis if patients on donepezil present with muscle weakness or pain,” study investigator Jamie Fleet, MD, Department of Physical Medicine and Rehabilitation at McMaster University, Hamilton, Ontario, Canada, told Medscape Medical News.

“There was some concern about the risk of rhabdomyolysis in donepezil use based on case reports. It was flagged by Health Canada and other regulatory agencies as a potential risk, which was one of the main reasons behind our study,” Fleet added.

https://www.medscape.com/viewarticle/918676?src=wnl_tp10n_191010_mscpedit&uac=1776MZ&impID=2124126&faf=1

 

Posted in Aging, Forensic Neuropsychiatry, Health, Psychiatry/Neurology | Tagged , , , , |

Walking Speed at Early Ages Tied to Cognitive Health

Walking Speed at Early Ages Tied to Cognitive Health

— Slowest walkers showed deteriorating cognitive performance from age 3 to adulthood

Gait speed at age 45 was a marker of cognitive and physical aging, a longitudinal cohort study showed.

Slow gait at age 45 was tied to accelerated biological aging across multiple organ systems and reduced brain volume and cortical thickness, according to Line J.H. Rasmussen, PhD, of Duke University in Durham, North Carolina, and co-authors.

Moreover, poor neurocognitive functioning as early as age 3 and deteriorating cognitive function from childhood to age 45 also were related to a slower midlife gait, the team reported in JAMA Network Open.

“Gait speed has been a routine test in geriatric medicine clinics, but it isn’t used anywhere else because the meaning and application of gait speed earlier in life has been unclear,” Rasmussen said.

Slow speed in this study was associated with “multiple indicators of accelerated aging and deteriorating organ function, much like in older adults, but already at the age of 45 years,” she told MedPage Today. “But the most remarkable thing was that we could predict how fast the participants walked at midlife by a childhood assessment of their cognitive functions at age 3: how well they did on an IQ test, how well they understood language, and how well they could master their emotions. Gait speed is not only an indicator of aging, but also an indicator of lifelong brain health.”

This work confirms that a subset of people in their 40s already are aging more quickly than their peers, observed Stephanie Studenski, MD, MPH, of the University of Pittsburgh School of Medicine, in an accompanying editorial. It suggests that unknown factors that had affected 3-year-old children may have influenced their function 40 years later, she added. “We should continue to learn more about how brains change across the life span, in terms of neural organization, connectivity, neurotransmitters, receptors, and subtle pathologic abnormalities,” she wrote.

“The human brain is dynamic; it is constantly reorganizing itself according to exposures and experience,” Studenski noted. “It is affected as an end organ by many other organ systems. Perhaps in this sense, brain health, reflected in brain structure, cognition, and gait speed, is not necessarily a first cause, but rather may be a consequence or mediator of lifelong opportunities and insults.”

In their analysis, Rasmussen and colleagues studied people from the Dunedin Longitudinal Study, who were born from April 1972 to March 1973 in New Zealand and who had been followed for 5 decades.

At age 45, participants had their gait speed measured under three conditions — normal walking, maximum walking speed, and dual-task speed (walking while reciting every other letter of the alphabet) — to calculate the primary measure of composite gait speed. Participants also took the Wechsler Adult Intelligence Scale-IVtest to assess their neurocognitive functioning, underwent brain MRIs, and had balance and strength tests at that age.

When participants were age 3, they had a 45-minute examination that included assessments by a pediatric neurologist, standardized tests of intelligence, receptive language, and motor skills, and examiner ratings of each child’s emotional and behavioral regulation. When the children were ages 7, 9, and 11, they took the Wechsler Intelligence Scale for Children–Revised.

At four points in the study — when participants were ages 26, 32, 38, and 45 — they had their physiological health assessed, including measurements of body mass index, waist-hip ratio, glycated hemoglobin, leptin, blood pressure, cardio-respiratory fitness, cholesterol, creatinine clearance, urea nitrogen, C-reactive protein, white blood cell count, and other markers. At age 45, a panel of raters also evaluated their facial aging.

Of the 904 participants who had their gait speed tested, 50.3% were male and 93% were white. Average gait speeds were 1.30 m/s for usual gait, 1.16 m/s for dual-task gait, and 1.99 for maximum gait.

Slow gait speed was related to accelerated biological aging across multiple organ systems (β −0.33; 95% CI −0.40 to −0.27; P <0.001), smaller brain volume (β 0.15; 95% CI 0.06 to 0.23; P< 0.001), more cortical thinning (β 0.09; 95% CI 0.02 to 0.16; P=0.01), smaller cortical surface area (β 0.13; 95% CI 0.04 to 0.21; P=0.003), and more white matter hyperintensities (β −0.09; 95% CI −0.15 to −0.02; P=0.01). Slow speed also was tied to poor balance and visual-motor coordination, weak strength, and older facial appearance.

People who had a lower IQ in midlife (β 0.38; 95% CI 0.32 to 0.44; P < 0.001) and participants who exhibited cognitive decline from childhood to adulthood (β 0.10; 95% CI 0.04 to 0.17; P < 0.001) had slower gait at age 45. People who had poor neurocognitive functioning at age 3 also had slower gait in midlife (β 0.26; 95% CI 0.20 to 0.32; P < 0.001).

This study had several limitations, the authors noted. Neither gait speeds nor brain imaging were assessed before age 45, and longitudinal changes in these measurements could not be seen. Unknown factors also may have influenced outcomes: “The markers of childhood brain health were all performance tests that might have been influenced by other important issues, such as sensory function, anxiety, familiarity with tasks, or how well a child felt on the day of testing,” Studenski noted.

Last Updated October 11, 2019

The study was funded by the U.S. National Institute on Aging, the U.K. Medical Research Council, the New Zealand Health Research Council, and the New Zealand Ministry of Business, Innovation, and Employment. Rasmussen was supported by the Lundbeck Foundation.

The researchers reported no conflicts of interest.

Studenski reported receiving personal fees from Merck, Inc. outside the submitted work.

https://www.medpagetoday.com/neurology/generalneurology/82702?xid=nl_mpt_SRNeurology_2019-10-11&eun=g1096159d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=NeuroUpdate_101119&utm_term=NL_Spec_Neurology_Update_Active

 

Posted in Aging, dietary, epigenetics, Events, Health, News, Psychiatry/Neurology | Tagged , , , |

Young Adults’ Wallet Woes May Harm the Brain in Midlife

Young Adults’ Wallet Woes May Harm the Brain in Midlife

-Findings emphasize how specific socioeconomic changes may negatively affect brain health

Study Authors: Leslie Grasset, M. Maria Glymour, et al.; Joel Salinas

Target Audience and Goal Statement: Neurologists, family physicians, primary care physicians

The goal of this study was to explore the relationship between income volatility in formative earning years and cognitive function and brain integrity in midlife.

Question Addressed:

  • What was the relationship between measures of income volatility in formative earning years and cognitive function and brain volumes/microstructural integrity in midlife?

Study Synopsis and Perspective:

Annual income drops of 25% or more during formative earning years may portend a greater likelihood of worse cognitive function and brain integrity in midlife, a prospective cohort study of Americans showed.

Action Points

  • Annual income drops of 25% or more during formative earning years may portend a greater likelihood of worse cognitive function and brain integrity in midlife, a prospective cohort study of Americans showed.
  • Understand that this study does not prove that drops in income cause reduced brain health, but it is possible that enhancing the stability of income could be of benefit.

 

https://www.medpagetoday.org/neurology/generalneurology/82700?xid=nl_mpt_DHE_2019-10-14&eun=g1096159d0r&utm_term=NL_Daily_DHE_Active&vpass=1

Posted in Fifth Avenue Concierge Medicine, Health, News, Psychiatry/Neurology | Tagged , , , , , , |

Fasting as a Therapy in Neurological Disease

Fasting as a Therapy in Neurological Disease

Department of Neurology, Waikato Hospital, Hamilton 3204, New Zealand
Nutrients 2019, 11(10), 2501; https://doi.org/10.3390/nu11102501
Received: 22 September 2019 / Revised: 12 October 2019 / Accepted: 15 October 2019 / Published: 17 October 2019
Fasting is deeply entrenched in evolution, yet its potential applications to today’s most common, disabling neurological diseases remain relatively unexplored. Fasting induces an altered metabolic state that optimizes neuron bioenergetics, plasticity, and resilience in a way that may counteract a broad array of neurological disorders. In both animals and humans, fasting prevents and treats the metabolic syndrome, a major risk factor for many neurological diseases. In animals, fasting probably prevents the formation of tumors, possibly treats established tumors, and improves tumor responses to chemotherapy. In human cancers, including cancers that involve the brain, fasting ameliorates chemotherapy-related adverse effects and may protect normal cells from chemotherapy. Fasting improves cognition, stalls age-related cognitive decline, usually slows neurodegeneration, reduces brain damage and enhances functional recovery after stroke, and mitigates the pathological and clinical features of epilepsy and multiple sclerosis in animal models. Primarily due to a lack of research, the evidence supporting fasting as a treatment in human neurological disorders, including neurodegeneration, stroke, epilepsy, and multiple sclerosis, is indirect or non-existent. Given the strength of the animal evidence, many exciting discoveries may lie ahead, awaiting future investigations into the viability of fasting as a therapy in neurological disease. View Full-Text

https://www.mdpi.com/2072-6643/11/10/2501

 

Posted in Aging, Fifth Avenue Concierge Medicine, Health, Psychiatry/Neurology | Tagged , , , , , , |

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

European Heart Journal, ehz754, https://doi.org/10.1093/eurheartj/ehz754
Published:
22 October 2019

Article history

Abstract

Aims

The Hygia Chronotherapy Trial, conducted within the clinical primary care setting, was designed to test whether bedtime in comparison to usual upon awakening hypertension therapy exerts better cardiovascular disease (CVD) risk reduction.

Methods and results

In this multicentre, controlled, prospective endpoint trial, 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) were assigned (1:1) to ingest the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory blood pressure (ABP) monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke). Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio—adjusted for significant influential characteristics of age, sex, type 2 diabetes, chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event—of the primary CVD outcome [0.55 (95% CI 0.50–0.61), P < 0.001] and each of its single components (P < 0.001 in all cases), i.e. CVD death [0.44 (0.34–0.56)], myocardial infarction [0.66 (0.52–0.84)], coronary revascularization [0.60 (0.47–0.75)], heart failure [0.58 (0.49–0.70)], and stroke [0.51 (0.41–0.63)].

Conclusion

Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events.

Trial registration

ClinicalTrials.gov, number NCT00741585.

 

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz754/5602478?utm_source=STAT+Newsletters&utm_campaign=e3979557de-MR_COPY_02&utm_medium=email&utm_term=0_8cab1d7961-e3979557de-118704797

 

 

Posted in Aging, Fifth Avenue Concierge Medicine, International And Concierge Medicine, News, Psychiatry/Neurology | Tagged , , , , |